BACKGROUND Oxaliplatin (OXA) is easy to cause sinusoidal obstruction syndrome (SOS), leading to liver injury. Isolinderalactone (ILL), one of the main components of Lindera aggregate, has been reported to have… Click to show full abstract
BACKGROUND Oxaliplatin (OXA) is easy to cause sinusoidal obstruction syndrome (SOS), leading to liver injury. Isolinderalactone (ILL), one of the main components of Lindera aggregate, has been reported to have a preservative effect on the liver. However, it is unclear whether ILL has a therapeutic effect on liver injury caused by OXA or not. This study aims to determine the effect of ILL on the prevention and treatment of OXA liver injury and to provide a basis for the chemotherapy of gastrointestinal tumors. METHODS Intraperitoneal injection of folinic acid, 5-fluorouracil, and OXA was administered on the SOS rat model for 7 weeks. The indexes of liver function were measured by biochemical kit. The ratio of liver weight to body weight was calculated. The pathological analysis of the liver was scored with the SOS scoring standard, fibrosis was evaluated with a four-point scale. The expression of inflammation factors was detected by Real-Time PCR, and the related indexes of IL-6/STAT3 were examined by Western blot analysis. RESULTS ILL down-regulated the portal vein pressure and alleviated the abnormal liver function of SOS rats and improved the liver lesions. ILL inhibited the SOS by inhibiting IL-6/STAT3. CONCLUSION ILL resistance to liver injury through inhibiting IL-6/STAT3 signal pathway.
               
Click one of the above tabs to view related content.